Patients diagnosed with migraine headaches saw a significant drop in their frequency when treated with medical cannabis, according to a new study.
Published in the journal Pharmacotherapy, the study examined patients diagnosed with migraines and treated with medical cannabis between January 2010 and September 2014.
It found the frequency of migraines dropped from 10.4 to 4.6 headaches per month, a number considered statistically and clinically significant, according to researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus.
Of the 121 patients studied, 103 reported a decrease in monthly migraines, while 15 reported the same number, and three saw an increase in migraines.
“There was a substantial improvement for patients in their ability to function and feel better,” said the study’s senior author, Laura Borgelt, Pharm.D., F.C.C.P. “Like any drug, cannabis has potential benefits and potential risks."
The researchers looked at the charts of patients treated at Gedde Whole Health, a private medical practice in Colorado that specializes in recommending cannabis for a variety of conditions. About two-thirds of the patients had a history of or were currently using cannabis at the time of their initial visit.
The researchers found various forms of cannabis utilized. Inhaled cannabis appeared to be the favorite for treating acute migraines, while edible cannabis, which takes longer to impact the body, helped prevent headaches.
Exactly how cannabis relieves migraines is still not fully understood, the researchers noted.
Cannabinoid receptors can be found throughout the body, including the brain, connective tissues and immune system. And they appear to have anti-inflammatory and pain-relieving properties, according to Borgelt. These cannabinoids also seem to affect critical neurotransmitters like serotonin and dopamine, she noted.
“We believe serotonin plays a role in migraine headaches, but we are still working to discover the exact role of cannabinoids in this condition,” Borgelt said.
She added that while the results were “quite remarkable,” more controlled studies are needed in the future.
The ideal study, she said, would be a randomized, placebo-controlled clinical trial with a cannabis washout period prior to start. It would also require providing subjects with standardized quantities and potencies of medical cannabis while tracking the occurrence of migraines just like prescription drug studies.
But given federal anti-drug laws, that kind of study would likely require legislative changes before it could be done, Borgelt said.
“If patients are considering medical cannabis they should speak to their health care provider and then follow up so we can track the impact of their overall treatment,” she said. “Open communication is necessary because we need to know how all of these treatments work together.”
- University of Colorado Anschutz Medical Campus.